Mindfulness Therapy for patients diagnosed with Schizophrenia
Not Applicable
- Conditions
- Health Condition 1: F20- Schizophrenia
- Registration Number
- CTRI/2019/07/020252
- Lead Sponsor
- Cross fertilized research training for new investigators in Egypt India Univ of Pittsburgh
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Closed to Recruitment of Participants
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients with a DSM-5 diagnosis of schizophrenia presenting to the Department of Psychiatry at PGIMER-Dr. R.M.L. Hospital, with a duration of illness of at least 1 year will be included in the study.
Exclusion Criteria
Patients with A comorbid psychiatric and/or neurological disorder will be excluded from the study.
Patients with previous experience with psychological intervention (in the preceding two years) will also be excluded from the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Patients in the MBSR group when compared to the Active Control group are expected to show improvements in symptoms of schizophrenia (PANSS), measures of mindfulness (Five Facet Mindfulness Questionnaire), executive (Trail Making Test) and cognitive functioning (Penn Neurocognitive Battery) and cognitive insight (Beck Cognitive Insight Scale)Timepoint: Patients will be assessed at 4 points during the study: at baseline (week 0), mid intervention (week 4), post intervention (week 8), at one month follow up (week 12)
- Secondary Outcome Measures
Name Time Method Patients in the MBSR group are expected to show improvement in overall quality of life as compared to the Active Control groupTimepoint: The assessment of quality of life will take place at 4 points in the study using WHOQOL-Bref: baseline (week 0), mid intervention (week 4), post intervention (week 8), at one month follow up (week 12).